The Center for Genetic Engineering and Biotechnology (CIGB), developer of the COVID-19 Abdala vaccine, celebrated the first anniversary of authorizing the emergency use of this immunogen for the pediatric population between two and 11 years of age .
Through Twitter, the scientific institute highlighted that said permission granted by the regulatory authority for medicines, equipment and medical devices in Cuba has ensured that the drug meets the required quality, safety and efficacy requirements.
“# 27October2021 #Today is the anniversary of @cubacecmed which authorizes the #emergency use of our #Abdala vaccine in the pediatric population between 2 and 11 years of age, as it meets the quality, #safety and # effectiveness required “, highlighted the CIGB.
The immunization scheme authorized by the Center for the State Control of Medicines, Equipment and Medical Devices (Cecmed) for this age group provides, as in adults, three doses of the drug and an interval of 14 days between each application.
Abdala, the first COVID-19 vaccine developed and manufactured in Latin America and the Caribbean, was authorized on July 9 for use in adults, after presenting the results of its Phase III clinical trial, which demonstrated a 92.28 percent efficacy in preventing symptomatic disease.
Cuba was the first country in the world to develop a National Campaign for Children against the pandemic, which managed to immunize over 1.6 million children and adolescents between the ages of two and 18.
The pediatric immunization process also included the anti-COVID-19 drugs Soberana 02 and Soberana Plus, developed by the Finlay Vaccine Institute.
